Early Signs and Symptoms of Ovarian Cancer
Ovarian cancer symptoms are subtle and easy to dismiss. Learn the signs worth a prompt clinician visit, why CA-125 alone is a poor screen, and where personalized detection fits.
Medically reviewed by Rhonda Collins, FNP-C | Mito Health on August 27, 2026.
Ovarian cancer is often called a silent disease, but it is not truly silent. It tends to cause subtle, persistent symptoms that are easy to blame on digestion, hormones, or a busy stretch of life. The signs worth knowing are bloating, pelvic or abdominal pain, feeling full quickly when eating, and urinary urgency or frequency. On their own these are common and usually harmless. What makes them worth acting on is a new pattern: symptoms that are frequent, persistent, and different from your normal. If that describes what you are feeling, see a doctor for evaluation rather than waiting it out.
What are the early signs and symptoms of ovarian cancer?
The Centers for Disease Control and Prevention and the American Cancer Society describe a recognizable cluster of symptoms. The four most consistently reported are:
- Bloating or a persistently swollen abdomen.
- Pelvic or abdominal pain or pressure.
- Feeling full quickly or difficulty eating, sometimes called early satiety.
- Urinary urgency or frequency, a sudden or more frequent need to urinate.
Other reported signs include fatigue, back pain, pain during sex, constipation, and changes in your menstrual cycle. The pattern that matters most is frequency and persistence. The American Cancer Society notes that when these symptoms are caused by ovarian cancer, they tend to be a change from normal and to occur almost daily, often more than 12 times a month. Occasional bloating after a big meal is not the concern. A new, near-daily change that lasts more than a few weeks is.
Why is ovarian cancer hard to detect early?
The ovaries sit deep in the pelvis, so a small tumor rarely causes obvious symptoms, and the symptoms it does cause overlap heavily with digestive and urinary complaints that most people experience at some point. There is also no recommended screening test for ovarian cancer in women at average risk. The US Preventive Services Task Force recommends against screening asymptomatic women who are not at high risk, because available tests have not been shown to reduce deaths and can lead to unnecessary surgery from false alarms.
Stage at diagnosis strongly shapes outcomes. Using NIH NCI SEER data, the survival gap between early and late detection is wide:
| Cancer | 5-year relative survival, distant stage | 5-year relative survival, localized stage |
|---|---|---|
| Ovarian | 31.8% | 91.7% |
| Breast | 32.6% | 99.9% |
| Colorectal | 16.2% | 91.5% |
Because most ovarian cancers are still found at a later stage, paying attention to that persistent symptom cluster is one of the few practical levers available today.
What raises the risk of ovarian cancer?
Knowing your risk helps you and your doctor decide how much attention symptoms deserve. The American Cancer Society describes risk factors that include:
- Family history of ovarian, breast, or colorectal cancer.
- Inherited gene changes, most notably BRCA1 and BRCA2 mutations, and Lynch syndrome.
- Older age, with most cases after menopause.
- Never having carried a pregnancy to term, and some patterns of hormone therapy after menopause.
- Endometriosis and certain reproductive conditions.
Family history and inherited mutations are the strongest signals. If close relatives have had ovarian or breast cancer, or if you carry a BRCA mutation, your doctor may recommend genetic counseling and a more intensive plan. Note that a blood-based screening test does not assess this inherited germline risk and is not a substitute for genetic counseling.
Is CA-125 a good screening test for ovarian cancer?
CA-125 is a protein that can be elevated in ovarian cancer, and you may have read that it can be tracked as an early warning. It has a real role, mainly in helping evaluate a known ovarian mass and in monitoring women already diagnosed. As a standalone screen for people without symptoms, it is unreliable. CA-125 can be raised by many benign conditions, including menstruation, endometriosis, uterine fibroids, pelvic inflammatory disease, and pregnancy, so it produces frequent false positives that can lead to anxiety and unnecessary procedures. It can also be normal in early ovarian cancer, producing false reassurance.
More broadly, single-marker screening tests carry a meaningful cumulative false-positive burden. In one analysis of standard screening approaches, Croswell and colleagues (Annals of Family Medicine, 2009) found a cumulative false-positive rate of roughly 43% across 14 screening exams. That is why guideline bodies do not endorse CA-125 for population screening. You can read more about what the marker measures on our CA-125 biomarker page and in our deeper look at CA125 screening for women in their 40s.
Where does personalized early detection fit?
If you have symptoms, the right step is a doctor’s evaluation, which may include a pelvic exam, transvaginal ultrasound, CA-125 in context, and specialist referral. A screening blood test is not the way to work up symptoms you already have.
For women without symptoms who are at higher risk, multi-cancer early detection (MCED) is emerging as a possible adjunct. Ovarian cancer is not part of the essential six-cancer Core panel, so ovarian coverage comes through personalization: with LucenceINSIGHT Me you and your doctor can add ovarian cancer to the panel from a curated list, alongside the core signals. It looks for cancer-associated signals from a single blood draw and is designed to complement, not replace, guideline screening and genetic counseling.
The limits are real. MCED does not diagnose cancer. Sensitivity varies by cancer type and stage, being included on the panel does not mean a cancer is equally detectable, and early-stage disease is harder to detect. A negative result does not mean you are cancer-free, and any positive signal needs confirmatory testing ordered by a doctor. To learn how MCED works overall, see our guide to multi-cancer early detection testing.
When should you see a doctor or seek urgent care?
See a doctor if bloating, pelvic or abdominal pain, early satiety, or urinary urgency are new for you, happen almost daily, and last more than two to three weeks. Bring your family history with you, since it changes how these symptoms are weighed. This is a reason for evaluation, not self-diagnosis.
Seek urgent medical care for severe or sudden abdominal or pelvic pain, a fever with pelvic pain, persistent vomiting, or a rapidly swelling abdomen. These can signal problems that need prompt attention.
If you have a strong family history or a known BRCA mutation, talk with your doctor about genetic counseling and a surveillance plan. Our cancer risk profile quiz can help you organize what to raise.
Ovarian cancer questions
What are the earliest symptoms of ovarian cancer? Bloating, pelvic or abdominal pain, feeling full quickly, and urinary urgency or frequency are the most commonly reported. They matter most when they are new, persistent, and near-daily.
Can a blood test detect ovarian cancer early? No test reliably detects it early in average-risk women without symptoms. CA-125 is not recommended as a standalone screen. Blood-based MCED is a screening adjunct for higher-risk people and does not diagnose cancer.
Is CA-125 worth checking? CA-125 is useful for evaluating a known mass and for monitoring an existing diagnosis. It is unreliable as a general screen because benign conditions raise it and it can be normal in early cancer.
Does a family history of breast cancer raise ovarian cancer risk? It can, particularly when a BRCA1 or BRCA2 mutation runs in the family. Talk with your doctor about genetic counseling if close relatives have had ovarian or breast cancer.
Related reading
- What is a multi-cancer early detection (MCED) test?
- CA-125: what the ovarian cancer biomarker measures
- Why CA125 screening matters for women in their 40s
- Building a personalized cancer screening plan after 40
Medical disclaimer
This article is for informational purposes only. It does not diagnose ovarian cancer or any other condition and does not replace medical care. Symptoms discussed here are non-specific and usually have benign causes. LucenceINSIGHT is a prescription screening adjunct for eligible people and does not diagnose cancer, does not replace guideline-recommended screening or genetic counseling, and is not a workup for existing symptoms. If you have concerning, persistent, or unexplained symptoms, see a qualified clinician, who can evaluate them in the context of your history, examination, and appropriate testing.
